JPMorgan Upgrades Integra LifeSciences (IART) to Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall as megacap tech drags; Iran developments watched
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China makes small dent in deflation battle as supply-demand imbalance persists
Integra LifeSciences (IART) Tops Q2 EPS by 3c; Updates FY15 Outlook
July 30, 2015 8:51 AM EDTIntegra LifeSciences (NASDAQ: IART) reported Q2 EPS of $0.79, $0.03 better than the analyst estimate of $0.76. Revenue for the quarter came in at $0 versus the consensus estimate of $239.91 million.
Integra LifeSciences sees FY2015 EPS of $3.00-$3.10, versus the consensus of $3.11. Integra LifeSciences sees FY2015 revenue of... More
